Table 4.
Compound | AChE |
BuChE |
||||
---|---|---|---|---|---|---|
In vitro | Computational |
In vitro | Computational |
|||
IC50 (µM) ± SEM | ΔG (kcal mol−1) | Ki (µM) | IC50 (µM) ± SEM | ΔG (kcal mol−1) | Ki (µM) | |
4 | 0.340 ± 0.007 | −6.29 | 24.54 | 0.499 ± 0.003 | −6.47 | 18.17 |
5 | 356.1 ± 4.73 | −5.29 | 132.58 | 0.553 ± 0.038 | −6.21 | 27.87 |
6 | 467.9 ± 4.98 | −5.05 | 197.98 | NT | −5.15 | 168.81 |
7 | 12.69 ± 0.62 | −6.16 | 30.68 | NT | −5.37 | 114.9 |
8 | 45.53 ± 1.36 | −6.21 | 28.08 | NT | −5.31 | 129.13 |
9 | 3.926 ± 0.014 | −6.51 | 16.96 | NT | −5.98 | 41.56 |
10 | 96.37 ± 2.81 | −5.6 | 78.3 | NT | −6.23 | 27.26 |
11 | 584.4 ± 7.92 | −5.03 | 205.05 | NT | −5.22 | 148.87 |
12 | 101.2 ± 1.58 | −5.63 | 74.59 | NT | −5.91 | 46.66 |
13 | 140.7 ± 3.11 | −5.46 | 99.58 | NT | −6.3 | 24.18 |
14 | 10.67 ± 0.56 | −6.08 | 34.85 | NT | −5.69 | 67.04 |
15 | 872.0 ± 4.38 | −5.4 | 109.84 | NT | −5.22 | 149.56 |
16 | 4.864 ± 0.81 | −6.68 | 12.76 | 1.757 ± 0.035 | −6.19 | 28.79 |
17 | 11.54 ± 0.35 | −6.38 | 21.08 | 0.024 ± 0.002 | −6.99 | 7.52 |
18 | 2.662 ± 0.084 | −7.3 | 4.46 | NT | −6.03 | 38.26 |
19 | 1.450 ± 0.047 | −7.05 | 6.8 | 5.718 ± 0.874 | −6.22 | 27.57 |
20 | 54.85 ± 0.92 | −5.77 | 58.85 | NT | −6.44 | 19.09 |
21 | 0.2645 ± 0.009 | −6.71 | 11.97 | 5.368 ± 0.278 | −6.33 | 23.02 |
DPZ | 0.021 ± 0.005 | −6.01 | 39.45 | – | – | – |
TAC | 0.225 ± 0.04 | – | – | 5.1 ± 0.2* | −5.35 | 119.26 |
Data from Ref. [60] and is expressed in nanomolars (nM).
NT – Not tested.Each IC50 value is the mean ± SEM. Level of statistical significance: p < .05 versus the corresponding IC50 values obtained against AChE, as determined by ANOVA/Dunnett’s. Reference inhibitors: DPZ – Donepezil, TAC – Tacrine.